Sign Up
OverviewAPI
Dyne Therapeutics, a clinical-stage muscle disease company, released promising initial trial results using their FORCE™ platform. The company bolstered its financial position with a $345 million public offering, ensuring funding until 2025. Dyne intends to refine dosages and offer trial progress updates in 2024.

Ask a question